Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
Go back to Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)| ADVAXIS (AMEX: ADXS) | Delayed: 0.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.60 | 52 Week High | $16.30 | |||
| Open | $0.60 | 52 Week Low | $5.21 | |||
| Day High | $0.60 | P/E | N/A | |||
| Day Low | $0.60 | EPS | $-4.10 | |||
| Volume | 380,864 | |||||
